Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-16
2006-05-16
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S419000, C514S002600
Reexamination Certificate
active
07045543
ABSTRACT:
This invention herein describes a method of facilitating the entry of drugs into cells and tissues at physiologically protected sites at pharmacokinetically useful levels and also a method of targeting drugs to physiologically protected sites in vivo. Also provided are drug conjugates with an amino acid or derivative thereof for facilitating such targeted drug delivery. The conjugates and methods of this invention provide an advance over other drug targeting methods known in the prior art, because the invention provides drug concentrations in such physiologically protected sites that can reach therapeutically-effective levels after administration of systemic levels much lower than are currently administered to achieve a therapeutic dose. This technology is appropriate for use with psychotropic, neurotropic, neurological, antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drugs, agents and conjugates, for rapid and efficient introduction of such agents across, e.g., the blood-brain barrier. Further, the invention provides means for retention and prolonged enzymatic release of such drugs, agents and conjugates comprising the conjugates of the invention, in the brain and central nervous system and other physiologically-protected sites.
REFERENCES:
patent: 5017566 (1991-05-01), Bodor
patent: 5023252 (1991-06-01), Hseih
patent: 5024998 (1991-06-01), Bodor
patent: 5039794 (1991-08-01), Wier et al.
patent: 5112863 (1992-05-01), Hashimoto et al.
patent: 5124146 (1992-06-01), Neuwelt
patent: 5149794 (1992-09-01), Yatvin et al.
patent: 5153179 (1992-10-01), Eibl
patent: 5177064 (1993-01-01), Bodor
patent: 5223263 (1993-06-01), Hostetler et al.
patent: 5254342 (1993-10-01), Shen et al.
patent: 5256641 (1993-10-01), Yatvin et al.
patent: 5258404 (1993-11-01), Ichinose et al.
patent: 5270312 (1993-12-01), Glase et al.
patent: 5284876 (1994-02-01), Shashoun et al.
patent: 5389623 (1995-02-01), Bodor
patent: 5405834 (1995-04-01), Bundgaard et al.
patent: 5413996 (1995-05-01), Bodor
patent: 5434137 (1995-07-01), Black
patent: 5442043 (1995-08-01), Fukuta et al.
patent: 5466683 (1995-11-01), Sterling et al.
patent: 5484809 (1996-01-01), Hostetler et al.
patent: 5484911 (1996-01-01), Hong et al.
patent: 5512671 (1996-04-01), Piantadosi et al.
patent: 5525727 (1996-06-01), Bodor
patent: 5543389 (1996-08-01), Yatvin et al.
patent: 5554728 (1996-09-01), Basava et al.
patent: 5563257 (1996-10-01), Zilch et al.
patent: 5580571 (1996-12-01), Hostetler
patent: 5696097 (1997-12-01), Matsuda et al.
patent: 5744461 (1998-04-01), Hostetler et al.
patent: 5744592 (1998-04-01), Hostetler et al.
patent: 5756116 (1998-05-01), Hostetler et al.
patent: 5756711 (1998-05-01), Zilch et al.
patent: 5827819 (1998-10-01), Yatvin et al.
patent: 5827831 (1998-10-01), Hostetler et al.
patent: WO 85/02342 (1985-06-01), None
patent: WO 89/11299 (1991-04-01), None
patent: WO 91/14438 (1991-10-01), None
patent: WO 94/01131 (1994-01-01), None
patent: WO 94/02178 (1994-02-01), None
patent: WO 94/03424 (1994-02-01), None
patent: WO 94/06450 (1994-03-01), None
patent: WO 95/07092 (1995-03-01), None
patent: WO 96/00537 (1996-01-01), None
patent: WO 96/04001 (1996-02-01), None
patent: WO 96/22303 (1996-07-01), None
patent: WO 98/03204 (1998-01-01), None
patent: WO 98/17325 (1998-04-01), None
Hardman et al. “Goodman & Gilman's The Pharmacological Basis of Therapeutics” (9th ed, 1996) p. 51 and 57-58.
CAS STN Registry: structures for amantadine and acyclovir; serotonin and melatonin, p. 1-4.
The Merck Index, Twelfth Edition, 1996, THER-17.
Boman et al., “Cell-free Immunity in Cecropia”, Eur. J. Biochem. (1991), 201, 23-31.
Lee et al., “Antibacterial peptides from pig intestine: Isolation of a Mammalian cecropin”, Proc. Natl. Acad. Sci. 1989, 86:9159-9162.
Lehrer et al., “Defensins: Edogenous Antibiotic Peptides of Animal Cells”, Cell, (1991), 64:229-230.
Zasloff et al., “Magainins, a class of Antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor”, Proc. Natl. Acad. Sci. (1997) 84:5449-5453.
Pederson Richard L.
Yatvin Milton B.
Cotton Abigail M.
EnzRel Inc.
McDonnell Boehnen & Hulbert & Berghoff LLP
Padmanabhan Sreeni
LandOfFree
Covalent conjugates of biologically-active compounds with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Covalent conjugates of biologically-active compounds with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Covalent conjugates of biologically-active compounds with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3526780